Poseida Net Working Capital from 2010 to 2024

PSTX Stock  USD 9.33  0.05  0.53%   
Poseida Therapeutics Net Working Capital yearly trend continues to be fairly stable with very little volatility. Net Working Capital is likely to outpace its year average in 2024. During the period from 2010 to 2024, Poseida Therapeutics Net Working Capital regression line of annual values had r-squared of  0.61 and arithmetic mean of  80,211,118. View All Fundamentals
 
Net Working Capital  
First Reported
2010-12-31
Previous Quarter
155.2 M
Current Value
155.2 M
Quarterly Volatility
97.6 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Poseida Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Poseida Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 9.1 M, Income Tax Expense of 112.3 K or Tax Provision of 112.3 K, as well as many indicators such as Price To Sales Ratio of 4.45, Dividend Yield of 0.0 or PTB Ratio of 4.84. Poseida financial statements analysis is a perfect complement when working with Poseida Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Poseida Therapeutics Correlation against competitors.
For more information on how to buy Poseida Stock please use our How to Invest in Poseida Therapeutics guide.

Latest Poseida Therapeutics' Net Working Capital Growth Pattern

Below is the plot of the Net Working Capital of Poseida Therapeutics over the last few years. It is Poseida Therapeutics' Net Working Capital historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Poseida Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Net Working Capital10 Years Trend
Slightly volatile
   Net Working Capital   
       Timeline  

Poseida Net Working Capital Regression Statistics

Arithmetic Mean80,211,118
Geometric Mean30,380,259
Coefficient Of Variation121.66
Mean Deviation84,484,942
Median8,581,000
Standard Deviation97,585,681
Sample Variance9523T
Range275.4M
R-Value0.78
Mean Square Error4017.7T
R-Squared0.61
Significance0.0006
Slope17,018,009
Total Sum of Squares133321.5T

Poseida Net Working Capital History

2024155.2 M
2023155.2 M
2022244.7 M
2021170.5 M
2020284 M
2019105.3 M
201819.6 M

About Poseida Therapeutics Financial Statements

Poseida Therapeutics investors use historical fundamental indicators, such as Poseida Therapeutics' Net Working Capital, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Poseida Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Working Capital155.2 M155.2 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Poseida Stock Analysis

When running Poseida Therapeutics' price analysis, check to measure Poseida Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Poseida Therapeutics is operating at the current time. Most of Poseida Therapeutics' value examination focuses on studying past and present price action to predict the probability of Poseida Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Poseida Therapeutics' price. Additionally, you may evaluate how the addition of Poseida Therapeutics to your portfolios can decrease your overall portfolio volatility.